Oncology

Intraoperative Radiotherapy for Breast Cancer (Intrabeam)

Intraoperative radiotherapy (IORT) delivers a single dose of radiation directly into the tumour bed during breast-conserving surgery, while you are still asleep. Intrabeam is the most widely used device: a miniature low-energy X-ray source with a ball-shaped applicator placed in the cavity left by the lumpectomy.

Save

Intraoperative radiotherapy (IORT) delivers a single dose of radiation directly into the tumour bed during breast-conserving surgery, while you are still asleep. Intrabeam is the most widely used device: a miniature low-energy X-ray source with a ball-shaped applicator placed in the cavity left by the lumpectomy.

For carefully selected early breast cancers it can replace 3 to 5 weeks of daily external radiotherapy. Local recurrence is slightly higher than with whole breast radiotherapy in trials, and about 1 in 5 women still need external radiotherapy once final pathology is known.

What Intraoperative Radiotherapy for Breast Cancer (Intrabeam) involves

Your case is first discussed by a breast multidisciplinary team, with mammography, ultrasound, often MRI and a core biopsy showing receptor status. On the day, the surgeon performs a wide local excision and sentinel lymph node biopsy. A spherical applicator of 1.5 to 5 centimetres is chosen to fit the cavity snugly and the breast tissue is drawn around it with a purse-string stitch. The skin edges are kept at least a centimetre away and the chest wall may be shielded. The radiation oncologist and physicist then deliver 20 gray at the applicator surface over 20 to 45 minutes. The applicator is removed and the wound closed as normal. Final pathology, ready about a week later, decides whether extra treatment is needed.

Who is a good candidate for Intraoperative Radiotherapy for Breast Cancer (Intrabeam)?

Guidelines restrict single-dose IORT to low risk disease, and the criteria matter more than the convenience.

It is usually not the right choice if:

Technique options

What happens during your treatment

IORT adds about 30 to 45 minutes to a lumpectomy, giving a total of 1.5 to 2.5 hours under general anaesthesia. You feel nothing of the radiation. Most women go home the same day or after one night with a small drain in some cases.

Preparing for your trip

Plan for 10 to 14 days, until final pathology in Istanbul. Your surgeon reviews photographs and your medical history before you book, and you meet in person the day before surgery for examination, marking and consent with a professional interpreter.

Recovery and results

Recovery is that of a lumpectomy: light activity in a few days, desk work in 1 to 2 weeks. The treated area may feel firm, and a fluid collection (seroma) is more common than after surgery alone. You must wait for final pathology before travelling home, because involved margins, positive nodes or unexpected lobular features mean re-excision or additional external radiotherapy. Hormone tablets for 5 years or more are prescribed by your oncologist at home.

Safety, risks and revision policy

Side effects are mostly local and milder on the skin than with external radiotherapy.

Every written proposal arranged through Clinic-Y states what the clinic covers if a correction is needed. Ask for it before you book, not after.

Cost of Intraoperative Radiotherapy for Breast Cancer (Intrabeam) in Türkiye

Clinic-Y does not publish a single price for Intraoperative Radiotherapy for Breast Cancer (Intrabeam), because the honest figure depends on your case. What moves it:

Send your photographs or reports and you receive written, all-inclusive proposals from suitable teams, side by side. Reviewing your case is free.

Frequently Asked Questions

Is IORT as safe as standard radiotherapy?

In the TARGIT-A trial survival was the same, with slightly more local recurrences when strict selection was followed. Some guideline bodies still advise using it with caution. Ask how your features compare with the trial criteria.

Why must I stay until pathology is back?

Because the full report may change the plan. Leaving before it is ready risks missing needed treatment.

Can men or younger women have it?

It is rarely advised under 50, where recurrence risk is higher and the evidence thin.

CallWhatsAppFree Quote